Ziad Khoury, MD
Cardiovascular Disease · Altoona, PANPI 1457357295
Payments from drug & device makers
Across 194 payments — averaging $768.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$72K
- AstraZeneca$49K
- Amgen$16K
- Boston Scientific$4K
- Abbott$2K
- Philips North America LLC$2K
- plus $5K from 31 others
What the payments were for
- Travel & lodging$4,0145%
- Food & beverage$8,35310%
- Other$71,96385%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 16 | $72,181 |
| AstraZeneca(2 entities) | 7 | $48,685 |
| Amgen(2 entities) | 16 | $16,489 |
| Boston Scientific | 23 | $3,601 |
| Abbott | 17 | $1,793 |
| Philips North America LLC | 4 | $1,527 |
| Biotronik Inc. | 8 | $882 |
| Lantheus Medical Imaging, Inc. | 1 | $630 |
| Medtronic(2 entities) | 4 | $554 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $343 |
| Inari Medical, Inc. | 4 | $253 |
| Johnson & Johnson | 28 | $228 |
| Novo Nordisk | 3 | $224 |
| Novartis | 11 | $154 |
| Pfizer | 13 | $151 |
| Ascensia Diabetes Care US Inc. | 1 | $132 |
| Smith+Nephew | 1 | $124 |
| Penumbra, Inc. | 1 | $119 |
| Cook Medical LLC | 2 | $98 |
| Irhythm Technologies, Inc. | 1 | $86 |
| Tactile Systems Technology Inc | 1 | $84 |
| Next Science LLC | 1 | $79 |
| E.r. Squibb & Sons, L.L.C. | 1 | $78 |
| Baxter Healthcare | 1 | $70 |
| Kowa Pharmaceuticals America, Inc. | 3 | $60 |
| Inspire Medical Systems, Inc. | 1 | $60 |
| Cordis US CORP. | 2 | $48 |
| Sunovion Pharmaceuticals Inc. | 3 | $47 |
| Organogenesis Inc. | 1 | $45 |
| Cequr Corporation | 1 | $40 |
| Amarin Pharma, Inc. | 2 | $36 |
| Cardiovascular Systems Inc. | 1 | $33 |
| Shockwave Medical, Inc | 2 | $31 |
| Greenwich Biosciences, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| GE HealthCare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$71,481
- WATCHMAN Access System$2,421
- IGT D Peripheral$1,338
- AVEIR$844
- Definity$630
- ACCENT$397
- WATCHMAN FLX$322
- Watchman$215
- ELLIPSYS VASCULAR ACCESS SYSTEM$186
- INCEPTIV$150
- CONCERTOTM$146
- FLOWTRIEVER CATHETER, S$138
- CT THROMBECTOMY SYSTEM KIT$138
- (5153) Azurion 5 M20 GC$133
- Acticor 7 VR-T DX$133
- EVERSENSE E3 SMART TRANSMITTER KIT$132
- GRAFIX PL$124
- RUBY Coil$119
How this compares
$149,029 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 730 | $632,316 |
| XareltoRivaroxaban | 358 | $347,988 |
| EntrestoSacubitril/Valsartan | 235 | $267,905 |
| Repatha SureclickEvolocumab | 266 | $178,336 |
| JardianceEmpagliflozin | 80 | $76,763 |
| BrilintaTicagrelor | 24 | $18,778 |
| Metoprolol Succinate | 897 | $18,428 |
| Repatha SyringeEvolocumab | 22 | $16,840 |
| Praluent PenAlirocumab | 19 | $13,923 |
| Rosuvastatin Calcium | 619 | $11,503 |
| Atorvastatin Calcium | 753 | $11,141 |
| ClopidogrelClopidogrel Bisulfate | 784 | $11,094 |
| Ranolazine ErRanolazine | 88 | $8,176 |
| Ezetimibe | 201 | $5,227 |
| Lisinopril | 456 | $4,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $151 | $632,316730 claims |
| Johnson & JohnsonXarelto | $228 | $347,988358 claims |
| NovartisEntresto | $154 | $267,905235 claims |
| Boehringer IngelheimJardiance | $18 | $76,76380 claims |
| AstraZenecaBrilinta | $48,685 | $18,77824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Altoona
- Danielle DuffyPhiladelphia$29.5M
- Venkatesh NadarCamp Hill$18.3M
- Hemal GadaWormleysburg$6.7M
- Brian DrachmanPhiladelphia$3.8M
- William BachinskyMechanicsburg$2.3M
- Bonnie KyPhiladelphia$1.9M
- Benjamin KalsmithPgh$1.7M
- Marielle Scherrer CrosbiePhiladelphia$1.6M
- Paul GrenaYardley$1.6M
- Peter KoweyWynnewood$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.